Suneva Medical, Inc., a San Diego, CA-based aesthetics company that markets dermal filler Bellafill® approved for the correction of facial acne scars, closed a $15m equity investment.
Almirall, Inc., an affiliate of Almirall, S.A, a global pharmaceutical company primarily focused within the therapeutic area of medical dermatology, made the investment. In addition to Almirall, which will receive one seat on Suneva Medical’s board of directors, other equity investors include HealthCare Royalty Partners and Polaris Ventures.
In addition, the company recently completed a $20.4m growth-capital term loan with an account managed by HealthCare Royalty Partners and increased the size of an existing working capital facility with Comerica Bank.
This company will use the proceeds for the ongoing launch of Bellafill®.
Led by Nicholas L. Teti, Jr., Chairman and Chief Executive Officer, Suneva Medical markets Bellafill® is a an FDA approved dermal filler for the correction of moderate to severe, atrophic, distensible facial acne scars on the cheek in patients over the age of 21 years.